OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY

被引：0
|
作者：
Seymour, J. F. [1 ]
Doehner, H. [2 ]
Kumar, R. [3 ]
Stone, R. M. [4 ]
Wierzbowska, A. [5 ]
Bernal del Castillo, T. [6 ]
Falantes, J. [7 ]
Delaunay, J. [8 ]
Sabloff, M. [9 ,10 ]
Voso, M. T. [11 ]
Kim, I. [12 ]
Ram, R. [13 ]
Gau, J. P. [14 ]
Songer, S. [15 ]
Lucy, L. M. [15 ]
Beach, C. [15 ]
Dombret, H. [16 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Univ Ulm Klinikum, Ulm, Germany
[3] Canc Care Manitoba, Winnipeg, MB, Canada
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Med Univ Lodz, Lodz, Poland
[6] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[7] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain
[8] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France
[9] Univ Ottawa, Ottawa, ON, Canada
[10] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[11] Univ Roma Tor Vergata, Rome, Italy
[12] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[13] Rabin Med Ctr, Petah Tiqwa, Israel
[14] Taipei Vet Gen Hosp, Taipei, Taiwan
[15] Celgene Corp, Summit, NJ USA
[16] Univ Paris Diderot, Inst Univ Hematol, Hop St Louis, Paris, France
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E954
引用
收藏
页码：381 / 381
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Sasaki, Koji
    Daver, Naval
    Issa, Ghayas C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Jain, Nitin
    Bhalla, Kapil N.
    Jabbour, Elias J.
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Rausch, Caitlin R.
    Malla, Rashmi
    Marek, Kelly
    Brandt, Mark
    Popat, Uday R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [42] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [43] Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.
    Bazinet, Alexandre
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas James
    Daver, Naval Guastad
    Issa, Ghayas C.
    Jain, Nitin
    Bull-Linderman, Debra
    Dinardo, Courtney Denton
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19018 - E19018
  • [44] Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
    Cortes, Jorge E.
    Heidel, Florian H.
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Candoni, Anna
    Leber, Brian
    Sekeres, Mikkael A.
    Pollyea, Daniel A.
    Ferdinand, Roxanne
    Ma, Weidong Wendy
    O'Brien, Thomas
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [45] Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
    Jorge E. Cortes
    Florian H. Heidel
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Anna Candoni
    Brian Leber
    Mikkael A. Sekeres
    Daniel A. Pollyea
    Roxanne Ferdinand
    Weidong Wendy Ma
    Thomas O’Brien
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Journal of Hematology & Oncology, 13
  • [46] AZACITIDINE PROLONGSOVERALL SURVIVAL IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH POOR PROGNOSTIC KARYOTYPES
    Doehner, H.
    Vyas, P.
    Seymour, J. F.
    Santini, V.
    Stone, R. M.
    Minden, M. D.
    Al-Ali, H. K.
    Bernal del Castillo, T.
    Morrill, J.
    Songer, S.
    Weaver, J.
    Skikne, B. S.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2017, 55 : S70 - S71
  • [47] Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)
    Mueller-Tidow, Carsten
    Tschanter, Petra
    Krug, Utz
    Goellner, Stefanie
    Roellig, Christoph
    Thiede, Christian
    Koschmieder, Anja
    Dugas, Martin
    Gerss, Joachim
    Butterfass-Bahloul, Trude
    Wagner, Ruth
    Krause, Stefan W.
    Kaiser, Ulrich
    Kunzmann, Volker
    Steffen, Bjoern
    Noppeney, Richard
    Herr, Wolfgang
    Baldus, Claudia D.
    Schmitz, Norbert
    Goetze, Katharina
    Reichle, Albrecht
    Kaufmann, Martin
    Neubauer, Andreas
    Schaefer-Eckart, Kerstin
    Haenel, Mathias
    Peceny, Rudolf
    Bea, Haack
    Meredith, Lilly
    Frickhofen, Norbert
    Kiehl, Michael G.
    Giagounidis, Aristoteles A. N.
    Goerner, Martin
    Repp, Roland
    Naumann, Ralph
    Link, Hartmut
    Kiani, Alexander
    Koschmieder, Steffen
    Bruemmendorf, Tim H.
    Serve, Hubert
    Ehninger, Gerhard
    Berdel, Wolfgang E.
    BLOOD, 2014, 124 (21)
  • [48] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Cavenagh, J. D.
    Kumar, R.
    Schuh, A. C.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    del Castillo, T. Bernal
    Al-Ali, H. K.
    Martinelli, G.
    Falantes, J.
    Nopenney, R.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L. M.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2015, 39 : S63 - S64
  • [49] Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
    Wei, Andrew
    Doehner, Hartmut
    Sayar, Hamid
    Ravandi, Farhad
    Montesinos, Pau
    Dombret, Herve
    Selleslag, Dominik
    Porkka, Kimmo
    Jang, Jun Ho
    Skikne, Barry
    Beach, C. L.
    Tian, Yu
    Chevassut, Timothy
    Roboz, Gail
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 54 - 55
  • [50] UPDATED RESULTS FROM A PHASE 2 STUDY OF PRACINOSTAT (P) IN COMBINATION WITH AZACITIDINE (AZA) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Garcia-Manero, G.
    Atallah, E.
    Khaled, S.
    Arellano, M.
    Patnaik, M.
    Esquibel, V.
    Wood, K.
    Medeiros, B.
    HAEMATOLOGICA, 2015, 100 : 216 - 216
12345